IMMUNE RECONSTITUTION IN PATIENTS WIHT B-NON HODGKIN LYMPHOMA (B-NHL) TREATED WITH RITUXIMAB, CHEMOTHERAPY OR BOTH - A COHORT STUDY

被引：0
|
作者：
Afonso, A. [1 ]
机构：
[1] Inst Portugues Oncol Lisboa Francisco Genti, Lisbon, Portugal
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1559
引用
收藏
页码：617 / 618
页数：2
相关论文
共 50 条
  • [1] Where is the place for rituximab in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) of children and adolescents?
    Patte, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 110 - 110
  • [2] Flow cytometric staging in B-non Hodgkin's lymphoma (NHL): Clinically useful or not?
    Holden, J. T.
    Kluin-Nelemans, J. C.
    Stetler-Stevenson, M. A.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2007, 72B (02) : 122 - 122
  • [3] Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Taniwaki, M.
    Ogura, M.
    Matsumoto, Y.
    Uchida, T.
    Ohmachi, K.
    Ando, K.
    Watanabe, T.
    Tobinai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Phase II study of oral Fludarabine (FAMP) in combination with rituximab in indolent B-cell non-hodgkin lymphoma (B-NHL)
    Ishizawa, Kenichi
    Tobinai, Kensei
    Ogura, Michinori
    Itoh, Kuniaki
    Aorishima, Yasuo
    Ando, Kiyoshi
    Yamamoto, Joji
    Watanabe, Takashi
    Uchida, Toshiki
    Nakata, Masanobu
    Hayashi, Masaki
    Hotta, Tomomitsu
    BLOOD, 2007, 110 (11) : 387A - 387A
  • [5] CD20 Positive Childhood B-non Hodgkin Lymphoma (B-NHL): Morphology, Immunophenotype and a Novel Treatment Approach: A Single Center Experience
    Bilic, Ernest
    Femenic, Ranka
    Konja, Josip
    Simat, Marija
    Dubravcic, Klara
    Batinic, Drago
    Ries, Suncica
    Rajic, Ljubica
    COLLEGIUM ANTROPOLOGICUM, 2010, 34 (01) : 171 - 175
  • [6] Glofitamab in Aggressive B Non-Hodgkin Lymphoma (B-NHL): A Real World Experience
    Chan, Thomas
    Kwong, Yok Lam
    Tse, Eric
    BLOOD, 2023, 142
  • [7] PREDICTIVE FACTORS FOR INFECTIOUS ADVERSE EVENTS IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA (B-NHL) TREATED WITH BENDAMUSTINE-RITUXIMAB (R) RESULTS OF A RETROSPECTIVE ANALYSIS
    Di Rocco, A.
    Petrucci, L.
    Ansuinelli, M.
    Vozzella, F.
    De Benedittis, D.
    Coggi, A.
    Foa, R.
    Martelli, M.
    HAEMATOLOGICA, 2017, 102 : 110 - 110
  • [8] Outcome of Relapse in Children/Adolescents with B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mature Acute Leukemia (B-AL) Treated in the Rituximab (R) Era
    Rigaud, C.
    Auperin, A.
    Jourdain, A.
    Schmitt, C.
    Paillard, C.
    Couec, M. L.
    Aladjidi, N.
    Gandemer, V.
    Lambilliote, A.
    Plat, G.
    Michon, J.
    Leblanc, T.
    Patte, C.
    Minard-Colin, V.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S36 - S36
  • [9] Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis
    Hua, Qingling
    Zhu, Yanzhe
    Liu, Hu
    JOURNAL OF CHEMOTHERAPY, 2015, 27 (06) : 365 - 370
  • [10] Acute agranulocytosis (AA) in three patients treated with rituximab for non Hodgkin lymphoma (NHL).
    Voog, E
    Brice, P
    Cartron, J
    Muller, JY
    Lazard, E
    Galanaud, P
    Solal-Celigny, P
    BLOOD, 2001, 98 (11) : 236B - 236B
12345